Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafamidis in Transthyretin Amyloid Cardiomyopathy
NCT01994889Phase 3Completed
- Sponsor
- Pfizer
- Start
- Dec 2013
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of tafamidis in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Pfizer. Started Dec 2013; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT01994889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01994889.